{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T11:33:51Z","timestamp":1788089631186,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-026-04758-6","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T09:16:40Z","timestamp":1787303800000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk factors for immune checkpoint inhibitor\u2013related thyroid dysfunction: a retrospective cohort study"],"prefix":"10.1007","volume":"91","author":[{"given":"Takahiro","family":"Amemiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"4758_CR1","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"S.C. Wei, C.R. Duffy, J.P. Allison, Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8, 1069\u20131086 (2018). https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0367","journal-title":"Cancer Discov"},{"key":"4758_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"J.J. Havel, D. Chowell, T.A. Chan, The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat. Rev. Cancer. 19, 133\u2013150 (2019). https:\/\/doi.org\/10.1038\/s41568-019-0116-x","journal-title":"Nat. Rev. Cancer"},{"key":"4758_CR3","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"P. Sharma, S. Goswami, D. Raychaudhuri, B.A. Siddiqui, P. Singh, A. Nagarajan, J. Liu, S.K. Subudhi, C. Poon, K.L. Gant et al., Immune checkpoint therapy\u2014current perspectives and future directions. Cell. 186, 1652\u20131669 (2023). https:\/\/doi.org\/10.1016\/j.cell.2023.03.006","journal-title":"Cell"},{"key":"4758_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12020-024-03718-2","volume":"85","author":"D Karaviti","year":"2024","unstructured":"D. Karaviti, E.R. Kani, E. Karaviti, E. Gerontiti, O. Michalopoulou, K. Stefanaki, P. Kazakou, V. Vasileiou, T. Psaltopoulou, S.A. Paschou, Thyroid disorders induced by immune checkpoint inhibitors. Endocrine. 85, 67\u201379 (2024). https:\/\/doi.org\/10.1007\/s12020-024-03718-2","journal-title":"Endocrine"},{"key":"4758_CR5","doi-asserted-by":"publisher","first-page":"1292122","DOI":"10.3389\/fimmu.2024.1292122","volume":"15","author":"T Yan","year":"2024","unstructured":"T. Yan, L. Yu, J. Zhang, Y. Chen, Y. Fu, J. Tang, D. Liao, Achilles\u2019 heel of currently approved immune checkpoint inhibitors: immune related adverse events. Front. Immunol. 15, 1292122 (2024). https:\/\/doi.org\/10.3389\/fimmu.2024.1292122","journal-title":"Front. Immunol."},{"key":"4758_CR6","doi-asserted-by":"publisher","unstructured":"I. Yamauchi, D. Yabe, Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors. Eur. Thyroid J. 14 (2025). https:\/\/doi.org\/10.1530\/ETJ-24-0328","DOI":"10.1530\/ETJ-24-0328"},{"key":"4758_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s00262-024-03816-0","volume":"74","author":"X Li","year":"2024","unstructured":"X. Li, Z. Song, Y. Chen, J. Wu, D. Jiang, Z. Zhang, Z. Wang, R. Zhao, Immune checkpoint inhibitors-related thyroid dysfunction: influencing factor analysis, prediction model development, and management strategy proposal. Cancer Immunol. Immunother. 74, 2 (2024). https:\/\/doi.org\/10.1007\/s00262-024-03816-0","journal-title":"Cancer Immunol. Immunother"},{"key":"4758_CR8","doi-asserted-by":"publisher","first-page":"R207","DOI":"10.1530\/EC-20-0342","volume":"9","author":"M Stelmachowska-Bana\u015b","year":"2020","unstructured":"M. Stelmachowska-Bana\u015b, I. Czajka-Oraniec, Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review. Endocr. Connect. 9, R207\u2013R228 (2020). https:\/\/doi.org\/10.1530\/EC-20-0342","journal-title":"Endocr. Connect."},{"key":"4758_CR9","doi-asserted-by":"publisher","first-page":"e1620","DOI":"10.1210\/clinem\/dgab829","volume":"107","author":"S Iwama","year":"2022","unstructured":"S. Iwama, T. Kobayashi, Y. Yasuda, T. Okuji, M. Ito, M. Ando, X. Zhou, A. Yamagami, T. Onoue, Y. Kawaguchi et al., Increased risk of thyroid dysfunction by PD-1 and CTLA-4 blockade in patients without thyroid autoantibodies at baseline. J. Clin. Endocrinol. Metab. 107, e1620\u2013e1630 (2022). https:\/\/doi.org\/10.1210\/clinem\/dgab829","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4758_CR10","doi-asserted-by":"publisher","first-page":"649863","DOI":"10.3389\/fendo.2021.649863","volume":"12","author":"L Zhan","year":"2021","unstructured":"L. Zhan, H.F. Feng, H.Q. Liu, L. Guo, C. Chen, X. Yao, S. Sun, Immune checkpoint inhibitors-related thyroid dysfunction: epidemiology, clinical presentation, possible pathogenesis, and management. Front. Endocrinol. 12, 649863 (2021). https:\/\/doi.org\/10.3389\/fendo.2021.649863","journal-title":"Front. Endocrinol."},{"key":"4758_CR11","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1210\/clinem\/dgac689","volume":"108","author":"JJ Wright","year":"2023","unstructured":"J.J. Wright, D.B. Johnson, Approach to the patient with immune checkpoint inhibitor\u2013associated endocrine dysfunction. J. Clin. Endocrinol. Metab. 108, 1514\u20131525 (2023). https:\/\/doi.org\/10.1210\/clinem\/dgac689","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4758_CR12","doi-asserted-by":"publisher","unstructured":"El R. Sabbagh, N.S. Azar, A.A. Eid, S.T. Azar, Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review. Int. J. Gen. Med. Volume. 1003\u20131009 (2020). https:\/\/doi.org\/10.2147\/IJGM.S261433","DOI":"10.2147\/IJGM.S261433"},{"key":"4758_CR13","doi-asserted-by":"publisher","first-page":"e1843","DOI":"10.1210\/clinem\/dgac059","volume":"107","author":"CA Muir","year":"2022","unstructured":"C.A. Muir, C.C. Wood, R.J. Clifton-Bligh, G.V. Long, R.A. Scolyer, M.S. Carlino, A.M. Menzies, V.H.M. Tsang, Association of antithyroid antibodies in checkpoint inhibitor\u2013associated thyroid immune\u2013related adverse events. J. Clin. Endocrinol. Metab. 107, e1843\u2013e1849 (2022). https:\/\/doi.org\/10.1210\/clinem\/dgac059","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4758_CR14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s40618-025-02732-z","volume":"49","author":"N Marrano","year":"2026","unstructured":"N. Marrano, M. Caporusso, C. Ganini, A. Borraccino, A. Cignarelli, S. Perrini, L. Laviola, C. Porta, F. Giorgino, A. Natalicchio, Risk factors for endocrinological immune-related adverse events in patients with renal cell carcinoma treated with immune checkpoint inhibitors. J. Endocrinol. Invest. 49, 399\u2013412 (2026). https:\/\/doi.org\/10.1007\/s40618-025-02732-z","journal-title":"J. Endocrinol. Invest."},{"key":"4758_CR15","doi-asserted-by":"publisher","unstructured":"M. Gilon, D. Boulet, V. Bours, G. Jerusalem, C. Josse, C. Gennigens, Eosinophils in solid cancers: sentinels, predictors, and therapeutic allies. J. Exp. Clin. Cancer Res. 45 (2026). https:\/\/doi.org\/10.1186\/s13046-026-03688-5","DOI":"10.1186\/s13046-026-03688-5"},{"key":"4758_CR16","doi-asserted-by":"publisher","first-page":"e1056","DOI":"10.1210\/clinem\/dgad231","volume":"108","author":"X Zhou","year":"2023","unstructured":"X. Zhou, S. Iwama, T. Kobayashi, M. Ando, H. Arima, Risk of thyroid dysfunction in PD-1 blockade is stratified by the pattern of TgAb and TPOAb positivity at baseline. J. Clin. Endocrinol. Metab. 108, e1056\u2013e1062 (2023). https:\/\/doi.org\/10.1210\/clinem\/dgad231","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4758_CR17","doi-asserted-by":"publisher","first-page":"992883","DOI":"10.3389\/fendo.2022.992883","volume":"13","author":"L Jing","year":"2022","unstructured":"L. Jing, Q. Zhang, Intrathyroidal feedforward and feedback network regulating thyroid hormone synthesis and secretion. Front. Endocrinol. 13, 992883 (2022). https:\/\/doi.org\/10.3389\/fendo.2022.992883","journal-title":"Front. Endocrinol."},{"key":"4758_CR18","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1038\/s41577-024-01048-y","volume":"24","author":"IC Arnold","year":"2024","unstructured":"I.C. Arnold, A. Munitz, Spatial adaptation of eosinophils and their emerging roles in homeostasis, infection and disease. Nat. Rev. Immunol. 24, 858\u2013877 (2024). https:\/\/doi.org\/10.1038\/s41577-024-01048-y","journal-title":"Nat. Rev. Immunol."},{"key":"4758_CR19","doi-asserted-by":"publisher","first-page":"eabb7495","DOI":"10.1126\/scitranslmed.abb7495","volume":"13","author":"Y Yasuda","year":"2021","unstructured":"Y. Yasuda, S. Iwama, D. Sugiyama, T. Okuji, T. Kobayashi, M. Ito, N. Okada, A. Enomoto, S. Ito, Y. Yan et al., CD4+ T cells are essential for the development of destructive thyroiditis induced by anti\u2013PD-1 antibody in thyroglobulin-immunized mice. Sci. Transl Med. 13, eabb7495 (2021). https:\/\/doi.org\/10.1126\/scitranslmed.abb7495","journal-title":"Sci. Transl Med."},{"key":"4758_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13601-019-0277-4","volume":"9","author":"PM Leru","year":"2019","unstructured":"P.M. Leru, Eosinophilic disorders: evaluation of current classification and diagnostic criteria, proposal of a practical diagnostic algorithm. Clin. Transl Allergy. 9, 36 (2019). https:\/\/doi.org\/10.1186\/s13601-019-0277-4","journal-title":"Clin. Transl Allergy"},{"key":"4758_CR21","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1038\/s41598-022-05400-x","volume":"12","author":"S Takayasu","year":"2022","unstructured":"S. Takayasu, S. Mizushiri, Y. Watanuki, S. Yamagata, M. Usutani, Y. Nakada, Y. Asari, S. Murasawa, K. Kageyama, M. Daimon, Eosinophil counts can be a predictive marker of immune checkpoint inhibitor-induced secondary adrenal insufficiency: a retrospective cohort study. Sci. Rep. 12, 1294 (2022). https:\/\/doi.org\/10.1038\/s41598-022-05400-x","journal-title":"Sci. Rep."},{"key":"4758_CR22","doi-asserted-by":"publisher","first-page":"11617","DOI":"10.1038\/s41598-021-91032-6","volume":"11","author":"K Manaka","year":"2021","unstructured":"K. Manaka, J. Sato, M. Takeuchi, K. Watanabe, H. Kage, T. Kawai, Y. Sato, T. Miyagawa, D. Yamada, H. Kume et al., Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency. Sci. Rep. 11, 11617 (2021). https:\/\/doi.org\/10.1038\/s41598-021-91032-6","journal-title":"Sci. Rep."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04758-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04758-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04758-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T09:16:41Z","timestamp":1787303801000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04758-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4758"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04758-6","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"28 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Ethical Guidelines for Life Sciences and Medical Research Involving Human Subjects and was approved by the Ethics Committee of the Faculty of Medicine, University of Tokyo (approval number: 2529).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee waived the requirement for informed consent due to the retrospective study design. An opt-out method was implemented in accordance with the Ethics Committee\u2019s requirements.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AI tools, including large language models and machine learning software, were used for the preparation, analysis, and presentation of this manuscript.","order":3,"name":"Ethics","label":"Artificial intelligence (AI) disclosure","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"285"}}